Tongjitang adjusts its board of directors

Nasdaq-listed and Shenzhen-based Tongjitang Chinese Medicines Co. , a manufacturer and marketer of modernized traditional Chinese medicines, said that it has removed the non-independent directors, Yongcun Chen, Xiaochun Wang and Justin Yan Chen from the audit committee, compensation committee and corporate governance and nominating committee, respectively, effective from March 14, 2008.

Each of these committees is now made up solely of the company's two independent directors Harry Genant and David Ray White. They will also form a special committee of the Board of Directors.

The purpose of this special committee is to purchase all of the outstanding ordinary shares of the company in a scheme of arrangement transaction under Cayman Islands law that will eventually result in the company becoming a privately held company, and to provide a proposal assessment to the company.

Earlier this month, Tongjitang Chinese Medicines had reported favorable financial results for 2007.

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, and Tongjitang Planting, is a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China.